dc.contributor.author | Akin, Ibrahim | |
dc.contributor.author | YILDIZ, Mustafa | |
dc.contributor.author | Yildiz, Banu Sahin | |
dc.contributor.author | Gursoy, Mustafa Ozan | |
dc.date.accessioned | 2021-03-03T08:57:38Z | |
dc.date.available | 2021-03-03T08:57:38Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | YILDIZ M., Yildiz B. S. , Gursoy M. O. , Akin I., "Recent developments in antiplatelet therapy after percutaneus coronary intervention", Cardiovascular and Hematological Disorders - Drug Targets, cilt.14, sa.3, ss.225-230, 2014 | |
dc.identifier.other | av_1a64b3d2-bcec-40f7-8cc3-8360fa0d27dd | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/23026 | |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84924095214&origin=inward | |
dc.identifier.uri | https://doi.org/10.2174/1871529x14666140823142031 | |
dc.description.abstract | © 2014 Bentham Science Publishers.Antiplatelet therapy plays an important role in the treatment of patients suffering from acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) in order to prevent atherothrombotic events and restenosis or ischemic reocclusion, respectively. Moreover, stent implantation is often performed along with PCI to ensure that the arteries remain open. However, stent thrombosis ST is a possible complication which can occur up to about one year after the procedure. Therefore, it is standard to treat patients with a dual antiplatelet regime whereby aspirin is combined with either clopidogrel, prasugrel or ticagrelor. This review summarizes the characteristics of these P2Y12 antagonists and evaluates the current and future clinical guidelines for antiplatelet therapy in the setting of PCI with or without stenting. | |
dc.language.iso | eng | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Biyoteknoloji | |
dc.subject | Temel Bilimler | |
dc.subject | Molecular Medicine | |
dc.subject | Life Sciences | |
dc.subject | Hematology | |
dc.subject | Pharmacology | |
dc.subject | Cardiology and Cardiovascular Medicine | |
dc.subject | Health Sciences | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Klinik Tıp | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Mikrobiyoloji | |
dc.subject | CARDIAC ve CARDIOVASCULAR SİSTEMLER | |
dc.subject | HEMATOLOJİ | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | BİYOTEKNOLOJİ VE UYGULAMALI MİKROBİYOLOJİ | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Hematoloji | |
dc.subject | Kardiyoloji | |
dc.subject | Eczacılık | |
dc.title | Recent developments in antiplatelet therapy after percutaneus coronary intervention | |
dc.type | Makale | |
dc.relation.journal | Cardiovascular and Hematological Disorders - Drug Targets | |
dc.contributor.department | İstanbul Üniversitesi , Su Bilimleri Fakültesi , Su Ürünleri Yetiştiriciliği Ve Hastalıkları Bölümü | |
dc.identifier.volume | 14 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 225 | |
dc.identifier.endpage | 230 | |
dc.contributor.firstauthorID | 2508049 | |